Various clinical trials investigating CAR-NK92 cell therapy: HER2 CAR-NK targeted Glioblastoma (NCT03383978), and chimeric costimulatory converting receptor (CCCR) CAR-NK against non-small cell lung cancer (NCT03656705). This evidence concerns the gene ERBB2 and glioblastoma.